Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: eternally (1)

Crizotinib Ver 1

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CRIZOTINIB This protocol may require funding Regimen NSCLC - Crizotinib Indication The treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CrizotinibVer1.pdf

Blinatumomab

Description: Chemotherapy Protocol Acute lymphoblastic leukaemia (ALL) Blinatumomab (3, 4 day) Regimen • ALL – Blinatumomab (3, 4 day schedule) Indication • Treatment of Philadelp
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Blinatumomab.pdf

Ceritinib 450mg

Description: Ceritinib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Ceritinib-450mg.pdf

Regorafenib

Description: Chemotherapy Protocol Gastro-Intestinal Stromal Tumour Regorafenib Regimen • GIST – Regorafenib Indication • Regorafenib is recommended for histologically confirmed me
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Regorafenib.pdf

Regorafenib

Description: Chemotherapy Protocol Hepatocellular Cancer Regorafenib Regimen • Hepatocellular – Regorafenib Indication • Regorafenib is recommended as an option for treating advanc
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Regorafenib.pdf

Everolimus-Exemestane

Description: Regimen Chemotherapy Protocol BREAST CANCER EVEROLIMUS and EXEMESTANE • Breast Cancer – Everolimus-Exemestane Indication • The first or second lin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Everolimus-Exemestane.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Pembrolizumab_400mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untreated PD-L1
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description: Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untreated PD-L1
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for l
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

41 to 50 of 220

Previous … 3 4 5 6 7 … Next